In 2008, the Center for Drug Evaluation (CDE) established the division of Health Technology Assessment (HTA), continuously promoting the Taiwanese model of HTA. Over the years, CDE HTA has gained recognition from various stakeholders, including the National Health Insurance Administration (NHIA), manufacturers, healthcare providers, and insured individuals, by adhering to principles that respect the value of scientific evidence. The ultimate goal of HTA is to support the health authority’s maximization of public health benefits. The HTA team primarily assesses the clinical comparative effectiveness and economic evaluation of new drugs and medical devices to support the NHI program’s decision making. The HTA team also conducts various HTA-related research projects commissioned by other health authorities under the Ministry of Health and Welfare (MOHW).
       In the early stages, CDE HTA primarily assisted the NHIA in conducting HTAs for the coverage of new drugs. Since 2011, CDE HTA has expanded its role to include the evaluation of medical devices for coverage applications under the national health insurance. These evaluations are primarily commissioned by the NHIA and adhere to established principles for conducting healthcare technology assessments. HTA researchers at the CDE, reflective of the characteristics of respective cases, perform effectiveness and economic review and assessment within 42 calendar days (including comparative effectiveness, cost-effectiveness and budget impact, etc.) of new drugs and medical devices proposed for coverage by the marketing authorization holder, collect related empirical scientific evidence and provide analytical reports of applicability in our country, which will be referred to during the review in the Pharmaceutical Benefit and Reimbursement Scheme (PBRS) Joint committee. CDE HTA team conduct comparative effectiveness and economic reviews and budget impact assessments within 42 calendar days for reimbursement applications of new drugs or medical devices submitted by marketing authorization holder. These assessment reports play a crucial role in informing decision-making for the Pharmaceutical Benefit and Reimbursement Scheme (PBRS) Joint Committee.
       Besides assisting the NHIA, HTA supports governmental health and welfare policies by providing sufficient scientific evidence to national health policymakers so that every bit of limited resources is well allocated. 
       Since 1 January, 2024. CDE HTA team expend our tasks to the assist the new drugs application’s  administrative review, HTA assessment and host the expert consultation meetings of new drugs, evaluation of managed entry agreements, HTAs of medical devices, providing scientic advice, horizon scanning, re-assessment and commissioned research projects of Health and Welfare policies.